GSK-J4 is thought to be effective in diffuse intrinsic pontine glioma (DIPG) (52), and the drug sensitivity of GSK-J4 is enhanced with increased expression of ESPL1. The gene discussed is ESPL1; the disease is diffuse intrinsic pontine glioma.